|
Abbott completes separation of research-based pharmaceuticals business
|
02 January 2013 |
|
Abbott announces three-year long-term data evaluating efficacy with HUMIRA® (Adalimumab)
|
22 October 2012 |
|
Abbott reports double digit earnings per share growth in the third quarter
|
17 October 2012 |
|
Abbott's HUMIRA® (adalimumab) receives FDA approval for the treatment of ulcerative colitis
|
30 September 2012 |
|
Abbott announces international launch of the Absorb(TM)
|
25 September 2012 |
|
Abbott to collaborate with Astellas in CMV vaccine trial
|
06 September 2012 |
|
Abbott reports second quarter results
|
18 July 2012 |
|
Abbott introduces OneLab, a novel integrated web-based software platform
|
11 July 2012 |
|
Seven pharmaceutical companies join academic researchers to speed TB drug discovery
|
08 July 2012 |
|
Abbott presents phase 3 study results for investigational use of HUMIRA® (Adalimumab)
|
06 June 2012 |
|
Abbott to Acquire Action Pharma's Investigational Compound, AP214
|
04 May 2012 |
|
Abbott's investigational treatment for advanced Parkinson's disease demonstrates positive results
|
18 April 2012 |
|
Abbott selects AbbVie as new name for future research-based pharmaceutical company
|
21 March 2012 |
|
Abbott reports double-digit ongoing earnings-per-share growth in fourth quarter and full-year 2011
|
25 January 2012 |
|
First-of-its-kind endovascular trial of the investigational Esprit(TM) therapy
|
22 December 2011 |
|
Abbott and Reata Pharmaceuticals Announce Agreement
|
12 December 2011 |
|
PATH, Abbott and the Abbott Fund Form Innovative Partnership to Prevent Malnutrition
|
03 November 2011 |
|
Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
|
01 November 2011 |
|
Abbott Reports Strong Ongoing Third Quarter Results
|
20 October 2011 |
|
Abbott to Separate into Two Leading Companies in Diversified Medical Products and Research-Based Pharmaceuticals
|
19 October 2011 |